1. Home
  2. ALLO vs KLTR Comparison

ALLO vs KLTR Comparison

Compare ALLO & KLTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • KLTR
  • Stock Information
  • Founded
  • ALLO 2017
  • KLTR 2006
  • Country
  • ALLO United States
  • KLTR United States
  • Employees
  • ALLO N/A
  • KLTR N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • KLTR EDP Services
  • Sector
  • ALLO Health Care
  • KLTR Technology
  • Exchange
  • ALLO Nasdaq
  • KLTR Nasdaq
  • Market Cap
  • ALLO 277.8M
  • KLTR 302.6M
  • IPO Year
  • ALLO 2018
  • KLTR 2021
  • Fundamental
  • Price
  • ALLO $1.21
  • KLTR $1.99
  • Analyst Decision
  • ALLO Strong Buy
  • KLTR Buy
  • Analyst Count
  • ALLO 9
  • KLTR 3
  • Target Price
  • ALLO $8.44
  • KLTR $2.83
  • AVG Volume (30 Days)
  • ALLO 2.5M
  • KLTR 369.0K
  • Earning Date
  • ALLO 08-06-2025
  • KLTR 08-07-2025
  • Dividend Yield
  • ALLO N/A
  • KLTR N/A
  • EPS Growth
  • ALLO N/A
  • KLTR N/A
  • EPS
  • ALLO N/A
  • KLTR N/A
  • Revenue
  • ALLO N/A
  • KLTR $180,920,000.00
  • Revenue This Year
  • ALLO N/A
  • KLTR $3.46
  • Revenue Next Year
  • ALLO $199.63
  • KLTR $3.67
  • P/E Ratio
  • ALLO N/A
  • KLTR N/A
  • Revenue Growth
  • ALLO N/A
  • KLTR 2.40
  • 52 Week Low
  • ALLO $0.86
  • KLTR $1.06
  • 52 Week High
  • ALLO $3.78
  • KLTR $2.82
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 43.73
  • KLTR 44.51
  • Support Level
  • ALLO $1.11
  • KLTR $1.92
  • Resistance Level
  • ALLO $1.29
  • KLTR $2.06
  • Average True Range (ATR)
  • ALLO 0.09
  • KLTR 0.11
  • MACD
  • ALLO -0.01
  • KLTR -0.00
  • Stochastic Oscillator
  • ALLO 25.81
  • KLTR 49.06

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About KLTR Kaltura Inc.

Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.

Share on Social Networks: